Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 16/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15938084 | 0.86 | MAPK3 (0.72) | MAPK3MAP3K7MAPK1MAP2K1FGFR1 | |
| SCHEMBL15948641 | 0.84 | MAPK3 (0.79) | MAPK3MAPK1MAP2K1 | |
| SCHEMBL18857471 | 0.80 | MAPK3 (0.75) | MAPK3MAPK1MAP2K1 | |
| SCHEMBL15938641 | 0.78 | MAPK3 (1.00) | MAPK3MAPK1MAP2K1 | |
| SCHEMBL18470027 | 0.78 | ALK (0.62) | MAPK3MAP3K7EGFRROS1ALK | |
| SCHEMBL15938621 | 0.78 | MAPK3 (0.83) | MAPK3EGFRROS1ALK | |
| SCHEMBL15948424 | 0.78 | MAPK3 (0.83) | MAPK3EGFRROS1ALK | |
| SCHEMBL15938385 | 0.78 | MAPK3 (1.00) | MAPK3EGFRROS1ALK | |
| SCHEMBL21894054 | 0.78 | MAPK3 (0.70) | MAPK3MAP3K7MAPK1MAP2K1FGFR1 | |
| SCHEMBL17409774 | 0.77 | MAPK3 (0.82) | MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MAPK3 3/4885MAP3K7 5/4885MAPK1 8/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | MAPK3 2/4885MAP3K7 5/4885MAPK1 1/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MAPK3 3/4885MAP3K7 5/4885MAPK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.